Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06533059 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
A Phase 1 study of Breast Cancer and Cancer, sponsored by Alterome Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
- 20
- Study locations
NCT06533059: Recruiting Phase 1 study of Breast Cancer and Cancer, sponsored by Alterome Therapeutics.
NCT06533059 is a Phase 1 study of Breast Cancer and Cancer that is actively recruiting participants, run by Alterome Therapeutics. The registered enrollment target is 110 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06533059, a Phase 1 study of Breast Cancer and Cancer, is actively recruiting participants, sponsored by Alterome Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
Primary Outcome
Number of participants that experience treatment-emergent adverse events (TEAEs).
Conditions Studied
Interventions
- DRUG ALTA2618
Study Locations (20)
Texas
- Research Site - Dallas
- Research Site - Houston
- Research Site #2 - San Antonio
- Research Site - San Antonio
California
- Research Site - La Jolla
- Research Site - Los Angeles
Massachusetts
- Research Site - Boston
- Research Site - Boston
New York
- Research Site - Mineola
- Research Site - New York
New South Wales
- Research Site - Blacktown
- Research Site - Randwick
Colorado
- Research Site - Denver
Florida
- Research Site - Sarasota
Georgia
- Research Site - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2024-08-22 |
| Est. Completion | 2027-12-29 |
| Phase | Phase 1 |
What NCT06533059 shows while recruiting
NCT06533059 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which ALTA2618 is the first listed.
NCT06533059 names 20 study sites across 13 states, led by Texas, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06533059 about?
NCT06533059 is a clinical study titled "A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors". The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
What is the current status of trial NCT06533059?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2024-08-22. Estimated completion is 2027-12-29.
What conditions does trial NCT06533059 study?
This clinical trial studies the following conditions: Breast Cancer, Cancer, Advanced Solid Tumor, Endometrial Cancer, Metastatic Cancer.
What interventions are being tested in trial NCT06533059?
The interventions under investigation include: ALTA2618 (DRUG).
Who is sponsoring clinical trial NCT06533059?
This trial is sponsored by Alterome Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06533059 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06533059's enrollment target sits among peer trials
110 536th of 1224 higher than 684 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
- NCT03245411 · 110 participants · NA
Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI